Elevated Serum Levels of Visfatin in Patients with Henoch-Schönlein Purpura

Cao, Na; Chen, Tao; Guo, Zongyou; Li, Meng Meng; Jiao, Xiao Yan

doi:10.5021/ad.2014.26.3.303

Cited by 8 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This biomarker has been studied for several inflammatory diseases such as obesity, metabolic syndrome, type 2 DM, polycystic ovary syndrome, and RA, but the findings are controversial [10][11][12][13][16][17][18]. Subsequent studies described visfatin upregulation in several immune cells including monocytes, lymphocytes, dendritic cells and macrophages [19][20][21]. Visfatin was shown to activate pro-inflammatory pathways and induce other proinflammatory cytokines including TNF-α, IL-1β and IL-6.…”

Section: Discussionmentioning

confidence: 99%

The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis?

Tanrıverdi

Iliaz

Çörtük

et al. 2017

Diffuse Parenchymal Lung Disease

View full text Add to dashboard Cite

Objective: Sarcoidosis is a chronic systemic inflammatory disease which can affect multiple organ systems. The role of biomarkers in the diagnosis and prognosis of sarcoidosis is increasing. Interest in the role of adipose tissue mediated inflammation in the pathogenesis of the inflammatory diseases has increased in recent years. Visfatin is a proinflammatory adipocytokine which has been studied for several inflammatory diseases such as diabetes mellitus, obesity and metabolic syndrome. Our aim is to assess serum visfatin levels in sarcoidosis and its relation with other markers of inflammation (CRP, ACE and ESR). Material and Methods: We enrolled 59 patients with sarcoidosis and 21 healthy controls. We measured plasma levels of visfatin along with serum CRP, ESR, ACE using ELISA (enzyme-linked immunosorbent assay) kits (Blue Gene Biotech, Shanghai, China). Results: Visfatin levels were not significantly different between patients and control subjects (29.9±15.8 ng/ml for patients and 23.93±16.73 ng/ml for controls, p=0.15) and there was no correlation between visfatin and serum CRP, ACE or ESR in patients with sarcoidosis. Conclusion: Visfatin recently is being discussed as biomarker for inflammatory diseases in several studies and results are controversial. In our study, no differences were found in serum level of visfatin between patients with sarcoidosis and control group.

show abstract

Section: Discussionmentioning

confidence: 99%

The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis?

Tanrıverdi

Iliaz

Çörtük

et al. 2017

Diffuse Parenchymal Lung Disease

View full text Add to dashboard Cite

show abstract

“…Henoch-Schönlein Purpura (HSP) is a systemic leukocytoclastic vasculitis mediated by immunoglobulin A (IgA) (1) and characterized by a series of clinical features, including non-thrombocytopenic palpable purpura, abdominal pain, arthritis and kidney damage (2). At present, the exact causes of HSP is unclear.…”

Section: Introductionmentioning

confidence: 99%

Henoch-Schönlein purpura following high-voltage electric burn injury: A case report and review of the literature

Duan

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Henoch-Schönlein Purpura (HSP) is a systemic vasculitis of unknown cause, with immune-mediated inflammation of the small vessels, which is characterized by a series of clinical symptoms, such as purpuric rash, colicky abdominal pain, arthritis and acute glomerulonephritis. Twenty-one days following a high-voltage electrical burn injury, a 40-year-old man developed classic clinical symptoms of HSP, including purpuric rash on bilateral lower extremities and abdominal pain. The patient was diagnosed with HSP associated with high-voltage burn injury, which is an extremely rare phenomenon. The diagnosis was based on the clinical manifestations of purpuric rash, abdominal pain and arthralgia, as well as the findings of laboratory examinations [increased levels of serum immunoglobulin A (11.6g/l) and complements C3 (9.6 g/l) and C4 (7.6 g/l), and a positive fecal occult blood test]. The patient was treated with antihistamines (loratadine tablets; 10 mg/day), anti-inflammatory medication (methylprednisolone sodium succinate; 40 mg/day) and oral omeprazole magnesium. The symptoms gradually decreased within 2 weeks from treatment and no abnormality was observed at the 3-, 6- and 12-month follow-ups. In patients who have suffered an electrical burn injury, this autoimmune disease may be caused by long-term inflammation. Therefore, examination of the liver and kidney functions of such patients is important in order to decrease the risk of post-traumatic immune system dysfunction.

show abstract

“… 5 β2GPI facilitates the diagnosis of HSP, 11 and visfatin is abnormally elevated in patients with HSP. 12 …”

Section: Discussionmentioning

confidence: 99%

Terminal Ileitis Induced by Henoch–Schonlein Purpura That Presented as Acute Appendicitis

Tian

Li³

et al. 2015

Medicine

View full text Add to dashboard Cite

Henoch–Schonlein purpura (HSP) is a self-limited autoimmune disease, the cause of which is not clear. Gastrointestinal involvement is often the main symptom of HSP. We report an unusual and rare case in a patient who was diagnosed with HSP. This is the second report of terminal ileitis induced by HSP that presented as acute appendicitis.We report a 21-year-old man who presented with right lower abdominal pain, and was diagnosed with acute appendicitis. Terminal ileitis was diagnosed intraoperatively, and when a rash occurred postoperatively, the final diagnosis was HSP.When the rash occurred, HSP was diagnosed and methylprednisolone was administered for 5 days.The diagnosis of HSP is difficult to establish, especially when the purpura occurs after gastrointestinal involvement; thus, abdominal pain should not be ignored and HSP should be considered.

show abstract

Elevated Serum Levels of Visfatin in Patients with Henoch-Schönlein Purpura

Cited by 8 publications

References 20 publications

The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis?

The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis?

Henoch-Schönlein purpura following high-voltage electric burn injury: A case report and review of the literature

Terminal Ileitis Induced by Henoch–Schonlein Purpura That Presented as Acute Appendicitis

Contact Info

Product

Resources

About